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Abstract Anti-VEGF-A therapy has become a mainstay
of treatment for ocular neovascularisation and in cancer;
however, their effectiveness is not universal, in some cases
only benefiting a minority of patients. Anti-VEGF-A
therapies bind and block both pro-angiogenic VEGF-Axxx
and the partial agonist VEGF-Axxxb isoforms, but their
anti-angiogenic benefit only comes about from targeting
the pro-angiogenic isoforms. Therefore, antibodies that
exclusively target the pro-angiogenic isoforms may be
more effective. To determine whether C-terminal-targeted
antibodies could inhibit angiogenesis, we generated a
polyclonal antibody to the last nine amino acids of VEGF-
A165 and tested it in vitro and in vivo. The exon8a poly-
clonal antibody (Exon8apab) did not bind VEGF-A165b
even at greater than 100-fold excess concentration, and
dose dependently inhibited VEGF-A165 induced endothe-
lial migration in vitro at concentrations similar to the
VEGF-A antibody fragment ranibizumab. Exon8apab can
inhibit tumour growth of LS174t cells implanted in vivo
and blood vessel growth in the eye in models of age-related
macular degeneration, with equal efficacy to non-selective
anti-VEGF-A antibodies. It also showed that it was the
VEGF-Axxx levels specifically that were upregulated in
plasma from patients with proliferative diabetic retinopa-
thy. These results suggest that VEGF-A165-specific anti-
bodies can be therapeutically useful.
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Introduction
Angiogenesis is implicated in the pathology of a range of
diseases with a vascular element and as a key mediator of
blood vessel growth, vascular endothelial growth factor
(VEGF) has been extensively studied as a critical protein in
pathological neovascularisation [8]. In 2002, the VEGF-A
isoform family VEGF-Axxxb was discovered and found to
possess significant anti-angiogenic properties [3, 25].
These VEGF-Axxxb isoforms can be distinguished from the
pro-angiogenic VEGF-A isoforms (VEGF-Axxx) by their
terminal exon selection. Proximal splice site selection in
the terminal exon, exon8a, encodes the terminal six amino
acid sequence of CDKPRR to create the VEGF-Axxx iso-
forms, whereas distal splice site selection (exon8b, 66 bp 30
from exon8a) creates the anti-angiogenic VEGF-Axxxb
isoforms with an altered 6 terminal amino acid sequence;
SLTRKD [13].
Analysis of expression of VEGF-Axxxb isoforms shows
they form a significant proportion of VEGF-A in most
normal, non-angiogenic tissues such as dorsal root ganglia
(71 %), lung (82 %) [3], skin ([95 %) [7], prostate [25],
colon ([95 %) [24] and vitreous (66 %) [16], but it is a
small proportion of the total VEGF-A concentration in
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angiogenic tissues such as placenta (1.4 %) [4]. Unlike
conventional VEGF-A isoforms, VEGF-A165b is down-
regulated in retinopathy and cancers such as renal cell
carcinoma, [3] colon carcinoma [24], prostate carcinoma
[25] and malignant melanoma [18].
Furthermore, VEGF-A165b expression inhibits VEGF-
A165 -mediated proliferation, migration and vasodilation
in vitro [3, 20, 21] as well as in vivo models of angio-
genesis including rat mesentery and rabbit cornea [25],
mouse skin and chick chorioallantoic membrane [23],
Matrigel implants [10], rat mammary gland [19], rat ovary
[1] and tumour models [21, 24].
The ability to detect VEGF-A in biological samples is
critical for the assessment of angiogenesis and commercial
panVEGF-A ELISA kits are widely available, with the
R&D Systems ELISA (DY293B, R&D Systems) one of the
most commonly cited. A method for VEGF-Axxxb isoform
detection in both laboratory and medical samples has
already been established [6, 16, 25] and a commercial
version has been available for several years (DY3045,
R&D Systems). However, similar products to specifically
detect VEGF-Axxx isoforms, as opposed to panVEGF, are
still relatively scarce. Thus, despite the important physio-
logical role that the balance of VEGF-Axxx and VEGF-
Axxxb isoforms has in angiogenesis, the ability to distin-
guish between each isoform family is severely limited
experimentally.
The lack of reliable assays is partly due to the success of
anti-VEGF-A therapies that bind both VEGF-Axxx and
VEGF-Axxxb isoforms that, at first glance, do not require a
distinction between isoforms. The application of such non-
specific therapeutics has been shown to be clinically suc-
cessful in the treatment of colorectal carcinoma (e.g. bev-
acizumab, Avastin) [9] and age-related macular
degeneration (AMD, e.g. ranibizumab, Lucentis) [11].
However, the application of anti-panVEGF-A therapeutics
has no effect on a sub-population of patients [9]. A recent
study in metastatic colorectal carcinoma patients showed
that only those patients with low VEGF-Axxxb:VEGFtotal
isoform ratios respond positively to bevacizumab therapy,
whilst those with a higher relative expression of VEGF-
Axxxb isoforms do not benefit from anti-VEGF-A therapy
[2]. Thus, the targeted inhibition of the pro-angiogenic
VEGF-Axxx isoforms without the loss of VEGF-Axxxb
isoforms is a more attractive therapy; inhibiting patholog-
ical angiogenesis without the loss of cytoprotective VEGF-
Axxxb required to maintain a healthy vasculature.
Here, we present data to show that targeted inhibition of
VEGF-Axxx isoforms with Exon8apab, a polyclonal anti-
body specific to the exon8a (CDKPRR) amino acid
sequence, is as effective as current anti-panVEGF-A ther-
apeutics but may be more physiologically applicable in the
treatment of VEGF-mediated pathologies.
Methods
Anti-VEGF-A165a antibody
Rabbits were immunized with a nine amino acid peptide
encoded by the C-terminal of VEGF-A165—
TCRCDKPRR—conjugated to KLH by Abgent Inc.
Plasma was taken and screened for VEGF-A165-specific
activity. One rabbit generated specific polyclonal antibod-
ies. Plasma was taken from this rabbit on at least three
occasions and activity confirmed. A final bleed was then
subjected to immunopurification by standard methodology.
Cell migration assay
Human umbilical vein endothelial cells (HUVECs) were
isolated as previously described and serum starved in
endothelial basal media (EBM) for 12 h. Cells were tryp-
sinized and re-suspended in 0.1 % FBS in EBM and 50,000
cells in 500 ll medium were seeded on attachment factor
(Cascade Biologics, Portland, OR, USA) coated filter
inserts (8 lm pore, 12 mm diameter, Millipore, Billerica,
MA, USA) with the treatment (1nM VEGF-A165a, with or
without VEGF-A antibody, or 10 % FCS as a positive
control) in the bottom well. Each treatment was performed
in triplicate. Cells were incubated at 37 C over night.
Inserts were washed with PBS and cells fixed with 4 %
PFA/PBS pH 7.4 for 10 min. The top of the membrane was
carefully cleaned with a sterile cotton bud, the membrane
stained with Hoechst 33258 (5 lg/ml in 0.5 % Triton/
PBS). Membranes were excised mounted bottom side up
on microscope slides with Vectashield (Vetorlabs, Burlin-
game, CA, USA). Cells were counted in 10 randomly
chosen fields away from the edge under a fluorescence
microscope (Nikon Eclipse T200). Cell migration was
expressed as the number of cells per high power field. The
inhibitory effect on migration of VEGF-A antibodies was
determined by increasing concentrations of antibody with
1 nM (40 ng/ml) VEGF-A165. IC50 was calculated from the
normalised data using a variable slope sigmoidal fit
(Prism4 software).
Laser-induced choroidal neovascularisation
Six- to eight-week-old C57/B6 mice (B&K Laboratories)
were anaesthetised with an intraperitoneal injection of a
mixture of 50 mg/kg ketamine and 0.5 mg/kg medetomi-
dine. The pupils were dilated with 2.5 % phenylephrine
hydrochloride and 1 % tropicamide. Four photocoagulation
lesions were delivered with a krypton red laser (mice:
250 mW, 0.01 s, 75 lm, rats: 200 mW, 0.01 s, 75 lm,
IRIS Medical 810 nm Oculight Slx laser) between the
‘‘large’’ retinal vessels in a peripapillary distribution at a
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distance of 1–2 optic disc diameters in each eye. Only laser
lesions with a subretinal bubble at the time of treatment
were included in the study. Immediately following laser
photocoagulation, the animals received intravitreal injec-
tions of 500 ng IgG in the control eye and 500 ng anti-
VEGF-A (G6-31) or 500 ng exon8a PAb in the treated eye
(day 0 and day 7). Animals were culled on day 14 and eyes
fixed, enucleated and choroids stained and examined.
VEGF-Axxx-specific ELISA
Immunoassay 96-well plates were coated with Exon8apab
antibody (25 lg/ml in 19 PBS, 100 ll/well) and left
overnight at room temperature. After washing in triplicate
(0.05 % Tween in 19 PBS, 200 ll/well), immunoassay
plates were blocked (1 % Bovine Serum Albumin in 19
PBS, 200 ll/well) and incubated at 37 C for minimum of
2 h. The plates were washed and samples added, using
recombinant human VEGF-A165 (840164, R&D Systems)
as a serial dilution control standard. Samples were assessed
in triplicate (100 ll/well, diluted in 1 %BSA/PBS). The
plate was then incubated at 37 C for 2 h with shaking.
Following washing, biotinylated goat anti-human pan-
VEGF-A detection antibody (BAF293, R&D Systems) was
added at 100 ng/ml in 1 %BSA/PBS (100 ll/well). The
plates were then incubated once more at 37 C for 2 h.
Following washing, HRP-conjugated streptavidin was
added (1:200 in 1 %BSA/PBS, 100 ll/well, 890803, R&D
Systems) and incubated without light exposure or agitation
for 30 min at RT. The plates were washed once more, and
HRP ELISA substrate (100 ll/well, DY999, R&D Sys-
tems) was added before a final incubation without light
exposure at RT for 15–30 min. A stop solution
(1 M H2SO4, 50 ll/well) was then added directly to the
substrate and resultant colour change measured at 450 nm
using an Opsys MR plate reader (Dynex, USA).
Plasma extraction and analysis
Patients were recruited from the vitrectomy clinics from
the Bristol Eye Hospital. All study participants were
Caucasians of Northern European origin. Ethics approval
for the study was obtained from the North Somerset and
South Bristol Research Ethics Committee and protocols
conformed to the tenets of the Declaration of Helsinki, as
revised in 2000. A venous blood sample was obtained from
each participant after informed written consent. Patient
samples were divided by diabetic status into three sub-
groups; proliferative diabetic retinopathy (PDR group,
n = 8), patients with non-proliferative diabetic retinopathy
(NPDR group, n = 11) and patients without diabetes (non-
diabetic/ND group, n = 22). Peripheral blood plasma was
separated by centrifugation (15 min at 2,0009g) and
aliquoted into individual vials (100–200 ll) for storage at
-80 C prior to the study. Assessment of VEGF-Axxxa
isoform concentrations were determined using the ELISA
protocol above, whereas VEGF-Axxxb isoforms were
assessed by ELISA as described in [6].
Tumour growth assays
2 9 106 LS174t colon cancer cells were prepared after
trypsinisation in 0.2 ml PBS and injected subcutaneously
in the dorsum of 6 nude Balb/C mice for each group. The
mice were monitored bi-weekly for tumour development.
Once tumours had developed mice were randomly allo-
cated to each of three groups and injected i.p. with either
50 lg bevacizumab, Exon8apab or mouse IgG in 100 ll
saline, coded and blinded for the injector and measurer.
Tumours were measured 3 days later and injected with a
second dose of the antibody. Animals were killed 7 days
later, because insufficient Exon8apab antibody was avail-
able for further treatment.
Results
Exon8apab is selective for VEGF-A165 over VEGF-
A165 b
Specificity of the antibody for the angiogenic phenotypes
was determined by ELISA (Fig. 1a) and Western blot
(Fig. 1b). Recombinant human VEGF-A165 but not VEGF-
A165b was detected by Exon8apab. The commercially
available VEGF-Axxxb-specific antibody MAB3045 (R&D
Systems) in the same assays detected VEGF-A165b but not
VEGF-A165. Using Exon8apab as a capture antibody for
VEGF-A protein in a sandwich ELISA assay showed
detection above background at 62.5 pg/ml (similar to
commercially available pan-VEGF-A antibodies), In con-
trast recombinant human VEGF-Axxxb was not detected
using Exon8apab even up to 2000 pg/ml.
Exon8apab inhibits endothelial cell migration
in response to VEGF-A165
Treatment of HUVEC cells with VEGF-A165 resulted in a
significant migration similar to that induced by 10 % serum
(Fig. 2a). This was dose dependently inhibited by treat-
ment with Exon8apab (IC50 = 0.115nM 95 % CI
0.07–0.19, Fig. 2b). Comparison with ranibizumab dem-
onstrated that the potency of the polyclonal antibody was
greater, but not statistically significantly so than that of a
panVEGF-A antibody (IC50 = 0.228, 95 % CI 0.17–0.311,
p = 0.059).
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Exon8apab slows tumour growth similarly to anti-
VEGF-A antibodies
To determine whether the antibody could inhibit tumour
growth, we treated LS174t heterotopic colon cancer
tumour bearing mice with bevacizumab or anti-VEGF-
A165 Exon8apab (n = 6 per group). Tumours were not
different in size after 1 week of implantation due to
matched allocation to treatment group. Three days after
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Fig. 1 Exon8apab is specific for VEGF-A165a. a An ELISA with
Exon8apab as a capture antibody and a biotinylated goat anti-human
panVEGF-A detection antibody with increasing concentration of
VEGF165a (closed circles) or VEGF165b (open circles) was carried
out. b Western blot using the two antibodies demonstrated specificity
of the Exon8apab for 20 ng recombinant human VEGF-A165a and a
monoclonal antibody to the c terminus of rhVEGF-A165b for 20 ng of
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Fig. 2 Exon8apab inhibits angiogenesis. a Endothelial cells were
seeded onto polycarbonate filters of transwell inserts. Increasing
concentrations of Exon8apab and 40 ng/ml rhVEGF-A165a was added
to the lower well. Cell migration across was measured by counting
cells on the lower side of the membrane 24 h after seeding. b The
experiment was repeated using either Exon8apab or ranibizumab.
IC50 was calculated using a variable slope dose inhibition curve
(Prism4.0). c LS174t cells (1 9 109) were implanted into nude mice
and tumours allowed to grow to approximately 200 mm3. Animals
were then treated with 2 mg/kg Exon8apab antibody at D0 and
treatment repeated at D3. Tumour volumes were measured once more
at D7. * p \ 0.05, one-way ANOVA, Bonferroni test
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significantly smaller than IgG treated tumours (Fig. 2c).
After 7 days, tumours from bevacizumab-treated mice
groups were smaller than the IgG controls, (p \ 0.05,
one-way ANOVA). Whilst 5/6 mice treated with Exo-
n8apab showed tumours comparable with the bev-
acizumab treatment group, the remaining tumour grew
significantly in those 4 days. As a result, whilst mean
tumour volume was comparable with bevacizumab, there
were no statistically significant differences between exo-
n8apab treatment and IgG controls at Day 7.
Exon8apab inhibited choroidal neovascularisation
As the tumour studies required substantial amounts of the
antibody, we used a laser-induced choroidal neovasculari-
sation (CNV) assay to determine the anti-angiogenic
activity of Exon8apab. In this model of angiogenesis,
intraocular treatment with Exon8apab (250 ng/ll) had
similar inhibitory effects to an anti-mouse VEGF-A anti-
body (250 ng/ll), with reduced lesion size at 7 days post-
photocoagulation (p \ 0.05, one-way ANOVA, Bonferroni
post hoc) (Fig. 3).
Exon8apab detects circulating VEGF-A165a
We used Exon8apab to detect circulating VEGF-A levels
in plasma from patients with diabetes. Non-diabetic
patients (ND), patients with non-proliferative diabetic ret-
inopathy (NPDR) and proliferative diabetic retinopathy
patients (PDR) had their venous blood plasma assessed for
VEGF-Axxxb using an ELISA method adapted from [6] and
VEGF-Axxx using Exon8apab. Of the 45 patients from
which plasma was collected VEGF levels were undetect-
able (\15 pg/ml) in 7. The remaining 83 % of patients had
plasma levels detected by either VEGF-A165b alone
(2 patients), or both isoforms (32 patients).
Assessment of VEGF-A concentrations in plasma
showed no statistically significant differences between the
different subgroups by VEGF-Axxx and VEGF-Axxxb
assessment (p [ 0.05, t test, Fig. 4a). However, there did
appear to be a trend with higher anti-angiogenic VEGF-
Axxxb in the ND/NPDR groups and higher pro-angiogenic
VEGF-Axxx in the PDR subgroup. When the proportion of
VEGF-A isoforms to combined total (VEGF-Axxx ?
VEGF-Axxxb = VEGFsum) was calculated, there appears to
be a consistent shift from VEGF-Axxxb predominating in
non-diabetics in favour of pro-angiogenic VEGF-Axxx in
the PDR group (Fig. 4b, p = 0.050 chi-squared test for
trend). Analysis within subgroups showed that non-diabetic
patients have no difference in the proportion of VEGF-
Axxxb (47.6 vs. 52.4 %). The non-proliferative diabetics
appear to show an intermediary balance of VEGF-Axxxb to
VEGF-Axxx (43.9 vs. 56.1 %), whereas in proliferative
diabetic patients the majority of VEGF-A produced is
VEGF-Axxx (81.1 vs. 18.9 % VEGF-Axxxb, p = \0.01
one-way ANOVA, Bonferroni test.).
Discussion
Here, we show that an antibody directed against the C
terminus of VEGF-A165 is able to inhibit VEGF-A165-
mediated cell migration, angiogenesis and tumour growth
in vivo and can be used to detect VEGF-A165 (but also
presumably other VEGF-Axxx isoforms) in human plasma.
The antibody generated was a polyclonal antibody from a
single rabbit. We attempted during this project to generate
monoclonal antibodies from mice both in house and com-
mercially and failed on three occasions. Moreover, only
one of six rabbits generated antibodies that were effective
in detecting VEGF-A165. The supply of the antibody is
therefore limited, and we surmise that antigenicity of the
peptide is relatively low. Interestingly, there have only ever
been two published antibodies against the C terminus of
VEGF-A165b—this one and the original VPF antibody
































Fig. 3 Exon8apab inhibits laser-induced CNV in mice. C57/B6 mice
underwent retinal lasercoagulation in both eyes (IRIDEX Oculight
GLX k—810 nm, 250 mV, 0.1 s, 75 lm, 4 lesions/eye). Animals
were subjected to intraocular injection with either 500 ng (250 ng/ll)
of an anti-mouse VEGF neutralising antibody, and control eyes
injected with either mouse IgG, or 500 ng (250 ng/ll) of Exon8apab
with a control rabbit IgG—controls administered at the same
concentration, directly after laser procedure (D0) and on day 7.
Staining with isolectin-B4 of the RPE-choroid-sclera complex
showed a decrease in lesion size for anti-VEGF and Exon8apab (N,
number of eyes; * p \ 0.05, one-way ANOVA, Bonferroni post hoc).
Merged lesions were excluded from the study. Scale bar 50 lm
Angiogenesis (2015) 18:23–30 27
123
polyclonals, and all other VEGF antibodies commercially
available, or available by collaboration have targeted either
exons 3–4 or exon 6 [17]. It is therefore clear that gener-
ation of C-terminal antibodies is not widely in use, and we
have not been able to generate specific antibodies with the
efforts described here. For this reason, only a preliminary
tumour study was carried out in mice, but the evidence we
have suggests that C-terminal antibodies targeting all
VEGF-Axxxa isoforms, when they can be generated, are at
least as effective as receptor binding domain antibodies
such as ranibizumab or bevacizumab at inhibiting VEGF-
A165.
These results raise a number of interesting questions.
First, it shows that it is possible to generate antibodies that
specifically target the pro-angiogenic isoforms of VEGF,
without affecting the anti-angiogenic, cytoprotective iso-
forms such as VEGF-A165b. This would result in antibodies
that do not suffer from the resistance associated with tar-
geting all VEGF isoforms in colon cancer for instance [2].
It may also result in safer, more effective anti-VEGF-A
therapies for eye disease, where long-term use of pan-
VEGF-A antibodies are associated with progressive vision
loss, possibly due to geographic atrophy [14].
These antibodies also raise the interesting likelihood that
conventional assessment techniques for measuring circu-
lating VEGF-A levels are inaccurate and could be replaced.
There are several limitations to the application of these
panVEGF-A assays. First, they are not applicable to all
sample types. For example, competition for epitopes
between antibodies and native molecules such as high
concentrations of the proteinase inhibitor a2-macroglobin
in human plasma are capable of binding VEGF-A and
therefore reduces anti-VEGF-A antibody binding by 82 %
[5]. Secondly, the inability for panVEGF-A detection
methods to distinguish between VEGF-Axxx and VEGF-
Axxxb isoforms means any alterations in splicing with
significant physiological implications will not be detected.
Thirdly, such panVEGF-A antibodies have different
affinities for the different isoform families. Assessment by
both ELISA and surface plasmon resonance showed that
the R&D Systems DuoSet panVEGF-A antibody only
detects 42 ± 0.4 % of VEGF-Axxxb, due to a difference in
binding affinity; 602 pM for VEGF-Axxx versus 3.98 nM
for VEGF-Axxxb, an *6.6-fold difference in affinity [24].
The results of such assays mean that the circulating levels
of VEGF-A found in normal plasma are regularly reported
at variously between 0 and 200 pg/ml, whereas early
assays using enzyme immunoassays (EIA) or differential
epitope antibodies put the concentration at[1 ng/ml. Here,
we show that in normal control patients the total VEGF-A
levels are around 4 ng/ml, of which 1.5 ng/ml is VEGF-
Axxx and 2.5 ng/ml is VEGF-A165b. This fits with early
methods, and with Western blots showing detectable levels
of VEGF-A in plasma when concentrated 109 (unpub-
lished data), suggesting that the original concentration of
the order of 1–10 ng/ml (200 pg/ml, even concentrated 10x
would require 1 ml of plasma to be loaded into a single
well of a SDS PAGE gel).
The results also suggest that the C-terminal tail of
VEGF-A165 is required for VEGFR activation. However,
crystallographic studies of VEGF-A have shown that it is
the amino acids encoded by exons 3 and 4, not exon 8, that
are the receptor binding domain [12]. Whilst the full length
VEGF including the C-terminal tail has never been crys-
tallised, and it has been shown that VEGF-A159 (a protein
missing the last six amino acids) is capable of both receptor
binding and inducing angiogenesis [23]. Crucially, despite
equal receptor binding affinity between VEGF-A165,
VEGF-A159 and VEGF-A165b, the C-terminal modulation
determines whether the response is angiogenic (receptor
activation) or anti-angiogenic (inhibitory). If the last few













































Fig. 4 Exon8apab measures VEGF levels in human plasma. VEGF
levels were measured in plasma from 32 patients, 5 of whom had
proliferative diabetic retinopathy (PDR), 11 non-proliferative diabetic
retinopathy (NPDR) and 18 control patients with no diabetes (ND).
a VEGF concentrations were measured by ELISA using either the
anti-VEGF-A165b as a capture antibody, or exon8apab as a capture
antibody. b The relative amount of the two isoforms was calculated as
a per cent of the total—e.g. 100*VEGF-Axxxb/(VEGF-Axxx-
a ? VEGF-Axxxb). * p \ 0.05 compared with VEGF-Axxxb,
Bonferroni
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interact with the receptor binding domain then an antibody
to the C terminus could disrupt that activation. In addition,
recent studies of the VEGFR co-receptor neuropilin-1
(Nrp-1) have shown that the C terminus of VEGF-A165,
particularly Arg-164, mediates high affinity binding of
Nrp-1, increasing VEGFR activity [15]. These results
therefore suggest that the C terminus of the VEGF-A
protein might be able to interact with the receptor binding
domain, or at least be brought within its vicinity during
receptor activation. Thus, the action of the Exon8apab
antibody must be interfering with the C terminus-neuro-
pilin/receptor binding domain interaction, presumably
through disruption to stoichiometric interaction.
It is clear that the work described here is preliminary, in
that significant amounts of antibody are not yet available
and monoclonal antibodies have not been produced, so the
effects on VEGFR phosphorylation, tumour angiogenesis,
or even longer term analysis of the effects on tumour
growth are yet to be deduced. However, these preliminary
data indicate that VEGF-Axxx-specific antibodies may have
considerable benefit both for research and diagnostically in
certain patients. Furthermore, VEGF-Axxx-specific anti-
bodies may provide the basis for a highly targeted and thus
more widely effective therapeutics than current anti-VEGF
therapies.
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